The Vanguard Group, Inc. recently announced the acquisition of new stake in Citius Pharmaceuticals Inc. (NASDAQ:CTXR). The institutional investor has increased its shareholding in the Healthcare company by 16.14% to 0.54 million shares with purchase of 74943.0 shares. This fresh investment now brings its stake to 1.19% valued currently at $0.7 million. In addition, Virtu Financial BD LLC raised its holdings by 91793.0 to 91793.0 shares.
With over 1.29 million Citius Pharmaceuticals Inc. (CTXR) shares trading Monday and a closing price of $0.95 on the day, the dollar volume was approximately $1.22 million. The shares have shown a negative weekly performance of -11.31% and its price on 08/24/20 lost nearly -6.04%. Currently, there are 41.60M common shares owned by the public and among those 39.36M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for CTXR have a consensus price objective of $5.50. The analysts have set the share’s price value over the next 12 months at a high of $7.00 and a low of $4.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Citius Pharmaceuticals Inc. stock is 2.00 for the next 12 months. But an upside of 86.43% will see the stock hit the forecast high price target while mean target price for the stock is $5.50.
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 2,793,297 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Citius Pharmaceuticals Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.44 million shares of the company’s stock, all valued at over $0.57 million. The company bought an additional 6300.0 shares recently to bring their total holdings to about 0.98% of the shares outstanding. Vanguard Extended Market Index Fu bought 26100.0 shares to see its total holdings expand to 0.13 million shares valued at over $0.17 million and representing 0.29% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.11% of the shares outstanding.
Shares of Citius Pharmaceuticals Inc. (NASDAQ: CTXR) opened at $1.01, unchanged from a prior closing price of $1.01. However, the script later closed the day at $0.95, down -6.04%. The company’s stock has a 5-day price change of -11.31% and 9.08% over the past three months. CTXR shares are trading -6.96% year to date (YTD), with the 12-month market performance down to -11.01% lower. It has a 12-month low price of $0.40 and touched a high of $1.97 over the same period. Currently, 1.29 million shares have been traded, compared to an average intraday trading volume of 3.28 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -18.78%, -19.68%, and 8.04% respectively.
Institutional ownership of Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares accounts for 13.00% of the company’s 41.60M shares outstanding. Mutual fund holders own 1.42%, while other institutional holders and individual stakeholders account for 27.24% and 0.73% respectively.
It has a market capitalization of $54.68M and a beta (3y monthly) value of 1.76. The earnings-per-share (ttm) stands at -$0.55. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.84% over the week and 6.87% over the month.
Analysts forecast that Citius Pharmaceuticals Inc. (CTXR) will achieve an EPS of -$0.1 for the current quarter, $0.33 for the next quarter and $0.71 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.11 while analysts give the company a high EPS estimate of -$0.1. Comparatively, EPS for the current quarter was -$0.16 a year ago. Earnings per share for the fiscal year are expected to increase by 33.90%, and 261.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Citius Pharmaceuticals Inc. (CTXR) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”